PMID- 19382992
OWN - NLM
STAT- MEDLINE
DCOM- 20090522
LR  - 20231213
IS  - 1365-2796 (Electronic)
IS  - 0954-6820 (Linking)
VI  - 265
IP  - 5
DP  - 2009 May
TI  - Autoimmune polyendocrine syndrome type 1 (APS-1) as a model for understanding 
      autoimmune polyendocrine syndrome type 2 (APS-2).
PG  - 530-40
LID - 10.1111/j.1365-2796.2009.02091.x [doi]
AB  - Autoimmune polyendocrine syndromes type 1 and 2 (APS-1 and APS-2) are diverse in 
      regards to their component diseases and immunologic features of pathogenesis. 
      Animal models and human studies highlight the importance of alleles of HLA (human 
      leukocyte antigen)-like molecules determining tissue specific targeting that with 
      the loss of tolerance leads to organ specific autoimmunity. Knowledge of the 
      syndromes and component diseases allows clinicians to recognize and prevent 
      illness prior to morbidity. With the current understanding of the syndromes, a 
      paradigm for diagnosis, screening and treatment can be established. Once 
      genetically susceptible individuals are identified screening for autoantibodies 
      can be performed. Amongst autoantibody positive individuals, monitoring for 
      physiologic decompensation, with a goal of treating prior to morbidity and in 
      some cases mortality, follows. With continued basic and clinical research, 
      therapies aimed at treating the underlying autoimmunity and disease prevention 
      should become possible.
FAU - Michels, A W
AU  - Michels AW
AD  - Department of Medicine, Barbara Davis Center for Childhood Diabetes, University 
      of Colorado, Denver, Aurora, Colorado 80045, United States. 
      Aaron.Michels@ucdenver.edu
FAU - Eisenbarth, G S
AU  - Eisenbarth GS
LA  - eng
GR  - AI15416/AI/NIAID NIH HHS/United States
GR  - AI50964/AI/NIAID NIH HHS/United States
GR  - DK057538/DK/NIDDK NIH HHS/United States
GR  - DK32083/DK/NIDDK NIH HHS/United States
GR  - DK32493/DK/NIDDK NIH HHS/United States
GR  - MO1 RR00051/RR/NCRR NIH HHS/United States
GR  - MO1 RR00069/RR/NCRR NIH HHS/United States
GR  - P30 DK57516/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - J Intern Med
JT  - Journal of internal medicine
JID - 8904841
RN  - 0 (Autoantibodies)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Transcription Factors)
SB  - IM
MH  - Adrenal Insufficiency/immunology
MH  - Animals
MH  - Autoantibodies/blood
MH  - Autoimmunity/genetics
MH  - Genetic Predisposition to Disease
MH  - Histocompatibility Antigens Class II/genetics
MH  - Humans
MH  - *Models, Immunological
MH  - Mutation
MH  - Polyendocrinopathies, Autoimmune/blood/diagnosis/*immunology
MH  - Self Tolerance/genetics
MH  - Syndrome
MH  - Transcription Factors/genetics
MH  - AIRE Protein
RF  - 75
EDAT- 2009/04/23 09:00
MHDA- 2009/05/23 09:00
CRDT- 2009/04/23 09:00
PHST- 2009/04/23 09:00 [entrez]
PHST- 2009/04/23 09:00 [pubmed]
PHST- 2009/05/23 09:00 [medline]
AID - JIM2091 [pii]
AID - 10.1111/j.1365-2796.2009.02091.x [doi]
PST - ppublish
SO  - J Intern Med. 2009 May;265(5):530-40. doi: 10.1111/j.1365-2796.2009.02091.x.